Daily Check-Ins We stay in touch and top of your challenges, successes and questions.
Recommended articles Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review Alorfi NM, Algarni AS Clinical Pharmacology: Advances and Applications 2022, 14:61-67 Published Date: 3 August 2022 Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice Chen X, Chen S, Ren Q, Niu S, Pan X, Yue L, Li Z, Zhu R, Jia Z, Chen X, Zhen R, Ban J Drug Design, Development and Therapy 2022, 16:3893-3913 Published Date: 9 November 2022 Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations Chao AM, Tronieri JS, Amaro A, Wadden TA Drug Design, Development and Therapy 2022, 16:4449-4461 Published Date: 29 December 2022 Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview Telci Caklili O, Cesur M, Mikhailidis DP, Rizzo M Diabetes, Metabolic Syndrome and Obesity 2023, 16:1767-1774 Published Date: 14 June 2023 GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway Xiang J, Qin L, Zhong J, Xia N, Liang Y Diabetes, Metabolic Syndrome and Obesity 2023, 16:2433-2446 Published Date: 15 August 2023
MMP9 is also used as a marker to evaluate mycotoxin illness/CIRS
Insurance Coverage & Cost Considerations Typically, insurance coverage favors FDA-approved use : Mounjaro is more likely to be covered when prescribed for diabetes
